Clinical Trial Update: Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating first-line treatment for HER2-negative breast cancer using Taxotere (docetaxel) followed by Myocet (liposomal doxorubic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Myocet (liposomal doxorubicin)
• Taxotere (docetaxel)

Snippet

Sponsor: Grupo Oncológico Gallego | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN